Business Context and Reporting Period
Rani Therapeutics Holdings, Inc. (RANI) filed a Form 8-K on May 26, 2026, reporting a significant capital raise event. The company, incorporated in Delaware and headquartered in San Jose, California, is an emerging growth company.
Key Financial Metrics and Transaction Details
The filing details a Securities Purchase Agreement entered into on May 26, 2026, with institutional investors. Key transaction metrics include:
- Securities Issued: 12,476,637 shares of Class A common stock and pre-funded warrants to purchase 6,214,953 shares.
- Offering Price: $1.07 per share of Class A common stock; $1.0699 per pre-funded warrant.
- Gross Proceeds: Approximately $20.0 million (before fees and expenses).
- Placement Agent Fees: 6.0% of aggregate gross proceeds payable to H.C. Wainwright & Co., LLC (lead) and Chardan Capital Markets LLC.
- Closing Date: Expected on or about May 27, 2026.
The filing does not provide current revenue, profit, cash flow, margin, or debt figures, as this is a current report regarding a specific event rather than a periodic financial statement.
Material Changes and Restrictions
The transaction introduces several material restrictions on the company's future capital activities:
- Issuance Lock-up: Rani agreed not to issue or announce the issuance of Class A common stock or equivalents for 90 days following the agreement date, with limited exceptions.
- Variable Rate Transactions: The company agreed not to enter into new variable rate transactions for nine months following the closing.
- Insider Lock-up: Directors, officers, and certain stockholders agreed to a 60-day lock-up period prohibiting the sale or transfer of Rani securities.
Outlook, Risks, and Management Commentary
The offering is being conducted pursuant to a registration statement on Form S-3 declared effective on August 14, 2025. The closing is subject to customary conditions. The filing notes that representations and warranties in the Purchase Agreement are subject to limitations and were made solely for the benefit of the parties to the agreement. No specific forward-looking guidance regarding clinical milestones or product development was included in this specific filing.
Investor Verification Checklist
- Verify the final closing date and confirmation of the $20.0 million gross proceeds.
- Review the definitive Securities Purchase Agreement (Exhibit 10.1) for specific exceptions to the 90-day issuance lock-up.
- Confirm the exact amount of placement agent fees and other offering expenses to calculate net proceeds.
- Monitor the company's cash runway post-closing to assess liquidity needs for the upcoming fiscal periods.
- Check for any subsequent filings regarding the exercise of the pre-funded warrants.